CTLA4 and non-small cell lung carcinoma: Furthermore, a meta-analysis incorporating 18 studies of NSCLC involving patients previously treated with anti-PD-(L)1 with or without anti-CTLA-4, and subsequently rechallenged with anti-PD-(L)1 after disease progression, demonstrated a pooled ORR of 8%, indicating a modest benefit [17].